|
"mirakhur b"的相關文件
顯示項目 1-10 / 19 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2020-10-10 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2019-07-28 |
Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2019-03-04 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T;Blanc, JF;Wang-Gillam, A;Chen, LT;Siveke, JT;Mirakhur, B;Chen, J;de Jong, FA |
| 國家衛生研究院 |
2019-02 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
|
Wang-Gillam, A;Hubner, RA;Siveke, JT;Von Hoff, DD;Belanger, B;de Jong, FA;Mirakhur, B;Chen, LT |
| 國立成功大學 |
2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T.;Blanc, J.-F.;Wang-Gillam, A.;Chen, L.-T.;Siveke, J.T.;Mirakhur, B.;Chen, J.;de, Jong F.A. |
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
|
Mercade, TM;Bodoky, G;Siveke, J;Lee, KH;Chen, J;Mirakhur, B;Dean, A;Chen, LT;de Jong, F |
| 國家衛生研究院 |
2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
|
Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J |
| 國家衛生研究院 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
|
Chen, LT;Macarulla, TM;Blanc, J;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, J |
| 國家衛生研究院 |
2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
|
Lakatos, G;Lee, K;Siveke, J;Blanc, J;Mercade, TM;Dean, A;Bodoky, G;Mirakhur, B;Chen, J;Wang-Gillam, A;Chen, L;de Jong, F |
顯示項目 1-10 / 19 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
|
